Synthesis of mesoporous materials as nano-carriers for an antimalarial drug

Abstract

An antimalarial drug artesunate (ATS) was encapsulated in both functionalized MCM-41 and ordinary MCM-41 with an excellent loading capacity and sustained release behavior for possible biomedical applications.

Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance

“…QN loading and release experiment were carried out as well for (MCM-41 ⊃ QN) 1 and (pMCM-41 ⊃ QN) 2 were similar to previous reports on (MCM-41 ⊃ ATS) 3 and (aMCM-41 ⊃ ATS) 4 nano drugs. The drug free MSNs prepared exhibited properties similar to our previous reported silica materials 29 . However, the loading of QN inside the pore of MSNs depicts new physicochemical properties for 1 and 2 .…”

“…In the search for improvement of the potency of antimalarial drugs, we set the hypothesis on novel nanocarrier MSNs envelopes/cargoesas good drug delivery system for QN and ATS, bearing in mind theirunique pore dimensions with high adsorptivities. Meanwhile, our previous research work on MSNs captured synthesis of MCM-41 and surface organically modified silica hybrids as vehicle for an antimalarial drug, ATS, with very high loading strength and satisfactory slow pharmokinetic release 29 . To the best of our knowledge as evidenced from literatures search, there has been no report on the use of MSNs for ATS and QN delivery system.…”

Promising nanomaterials in the fight against malaria

“…141,142 Amolegbe et al have studied the potential of mesoporous MCM-41 as a carrier for antimalarial drugs. 143,144 MCM-41 is a silicate/aluminosilicate mesoporous molecular sieve synthesized by Beck et al using liquid crystal templates. 145 With the aim of improving bioavailability, unmodified MCM-41 and MCM-41 pore-functionalized with either amino (aMCM-41) or phenyl groups (pMCM-41) were tested to encapsulate ATS, a drug with a short half-life in blood, 143 and QN, a lipophilic drug that can cause severe adverse effects at therapeutic doses.…”

“…143,144 MCM-41 is a silicate/aluminosilicate mesoporous molecular sieve synthesized by Beck et al using liquid crystal templates. 145 With the aim of improving bioavailability, unmodified MCM-41 and MCM-41 pore-functionalized with either amino (aMCM-41) or phenyl groups (pMCM-41) were tested to encapsulate ATS, a drug with a short half-life in blood, 143 and QN, a lipophilic drug that can cause severe adverse effects at therapeutic doses. 144 The interactions between MSNs and the drug determined the release profile, whereby aMCM-41 showed slow release of ATS due to hydrogen-bonding interactions between the amino groups in the MSNs and the ATS carboxylic group.…”

“…Such slow release of the drug can make these MSNs also interesting for oral administration. 143 Regarding QN, the functionalization of pMCM-41 with phenyl rings appeared as a useful strategy to increase the drug loading capacity and give better controlled release. 144 Both systems were tested in vitro against P. falciparum and in vivo against P. berghei-infected mice.…”